The Hedge Funds Poised to Profit From a Drug Maker’s IPO

At least four hedge funds are prominent investors in Satsuma Pharmaceuticals, one of the latest biopharma companies seeking to go public. They control nearly half of its shares.The largest investor is RA Capital Management with about 15.7 million of Satsuma's common shares, or a 30.2 percent stake, according to a preliminary prospectus filed